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Abstract.  
Excessive alcohol intake is associated with 5.9% of global deaths. However, this figure is 
especially acute in men such that 7.6% of deaths can be attributed to alcohol intake. Previous 
studies identified a significant interaction between genotypes of the galanin (GAL) gene with 
anxiety and alcohol abuse in different male populations but were unable to define a 
mechanism. To address these issues the current study analysed the human UK Biobank 
cohort and identified a significant interaction (n=115,865; p=0.0007) between allelic variation 
(GG or CA genotypes) in the highly conserved human GAL5.1 enhancer, alcohol intake 
(AUDIT questionnaire scores) and anxiety in men. Critically, disruption of GAL5.1 in mice 
using CRISPR genome editing significantly reduced GAL expression in the amygdala and 
hypothalamus whilst producing a corresponding reduction in ethanol intake in KO mice. 
Intriguingly, we also found evidence of reduced anxiety-like behaviour in male GAL5.1KO 
animals mirroring that seen in humans that was consistent with our previous UK Biobank 
studies. Using bioinformatic analysis and co-transfection studies we further identified the 
EGR1 transcription factor, that is co expressed with GAL in amygdala and hypothalamus, as 
being important in the protein kinase C (PKC) supported activity of the GG genotype of 
GAL5.1 but less so in the CA genotype. Our unique study uses a novel combination of human 
association analysis, CRISPR genome editing in mice, animal behavioural analysis and cell 
culture studies to identify a highly conserved regulatory mechanism linking anxiety and alcohol 
intake that might contribute to increased susceptibility to anxiety and alcohol abuse in men.  
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Background.  
The relationship between alcohol abuse and anxiety has been extensively explored 1 but 
the genomic mechanisms linking them remain poorly understood.  Previous studies have 
shown that the galanin neuropeptide (encoded by the GAL gene) influences alcohol intake 2, 3 
and anxiety-like behaviour4. Moreover, genetic analyses of different genotypes within the GAL 
locus succeeded in identifying an association with excess alcohol intake that was influenced 
by sex and anxiety5. Unfortunately, these studies were unable to define a mechanism to 
explain these interactions as the GAL coding region lacks non-synonymous polymorphisms5. 
Although there is a possibility that mis-regulation of GAL may affect alcohol intake and anxiety, 
little is known of the genomic mechanisms that modulate the expression of the GAL gene in 
the brain.   
Based on the hypothesis that regions of the genome essential to species fitness are 
conserved through evolution 6, 7, we undertook a comparative genomic analysis of the genome 
surrounding the human GAL locus and succeeded in identifying a highly conserved enhancer 
sequence (hGAL5.1) 42 kilobases (kb) from the GAL gene transcriptional start site8.  We 
demonstrated that hGAL5.1 was active in galanin expressing cells of the hypothalamus 
including the PVN and dorsomedial hypothalamus (DMH)8. We also found that GAL5.1 
contained two polymorphisms in perfect linkage disequilibrium (LD; rs2513280 (C/G) and 
rs2513281 (A/G)) that produced two different genotypes (GG and CA) within the human 
population and reported that the major GG genotype was significantly more active in primary 
hypothalamic neurones than the minor CA genotype 8. Analysis of these genotypes in human 
populations detected an association of the GG genotype and volume of alcohol intake in 
women in a small US cohort (n=138) 9. However, a second UK (n=2731) and US cohort 
(n=4064) based study, although initially identifying an association to increased frequency of 
binge drinking in teenagers, failed to reach significance after correction for multiple 
comparison 10. Because of the comparatively small size of these studies we interrogated a 
much larger human cohort (UK biobank) to better determine the association of specific allelic 
variants in GAL5.1 with levels of alcohol intake and anxiety in UK men and women. In addition, 
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we used CRISPR genome editing to disrupt GAL5.1 in mice and examined the effects on the 
expression of flanking genes in areas of the brain including the hypothalamus and the 
amygdala to functionally link GAL5.1 activity to the expression of five flanking genes including 
Gal. Our study also characterises the effects of GAL5.1 disruption on ethanol consumption 
and anxiety-like behaviour in mice. In addition, a combination of bioinformatics (DNAseI 
hypersensitivity) and co-transfection studies identified a transcription factor-DNA interaction 
underpinning GAL5.1 function and its response to signal transduction cues. This study 
highlights a novel mechanistic link between ethanol consumption and anxiety centred on the 
GAL5.1 enhancer that may contribute to the development of alcohol abuse and anxiety in 
men11, 12.  
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Methods. 
Genetic Association Study in humans. Genetic association analyses with alcohol 
consumption (units consumed per week) were performed using BGENIE, version 1 13 with 
alcohol consumption as the outcome variable and age, sex, genotyping array and the first 20 
genetic principal components as covariates. We then split the sample into males and females 
and repeated the association analysis, removing sex as a covariate. The mean alcohol intake 
in the total population was 15.3 units per week (S.D.=16.0). The mean age of the population 
was 56.2 years (S.D. = 8.0). Men self-reported higher weekly alcohol intake compared to 
women (20.7 units (S.D.=18.4) vs 10.5 units (S.D.=11.5).  Analysis of the association of 
alcohol intake and allelic variation at the rs2513280 locus was undertaken on a population of 
345,140 individuals (UK Biobank (UKB); 183,921 females and 161,219 males all unrelated 
White British individuals).  
To analyse the interaction effect of rs2513280 and anxiety on alcohol use behaviour in 
humans we also analysed a subset of the UK Biobank14 who had responded to a mental 
health questionnaire (MHQ) the results of which were made available to researchers in August 
2017 15. The MHQ had information on anxiety and in this follow-up alcohol use was 
ascertained using the AUDIT (Babor, 1991: The Alcohol Use Disorders Identification Test – 
Guidelines for Use in Primary Care. World Health Organ - Dep Ment Health Subst Depend 
2001); a 10-item questionnaire used to measure both alcohol consumption and problematic 
drinking. AUDIT total scores range from 0-40 and the derivation of this measure in the UKB 
has been described previously in greater detail 16. For both sets of alcohol analyses, former 
and never drinkers were removed. 
Anxiety was ascertained by asking participants "Over the last 2 weeks, how often have 
you been bothered by any of the following problems? Feeling nervous, anxious or on edge" 
[UKB data field 20506]. Anxiety was then dichotomized by comparing those answering 'Not at 
all' to individuals endorsing 'Several days', 'More than half the days' or 'Every day'. After 
filtering the MHQ subset of individuals on those who were White, British and unrelated with 
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and non-missing data there remained 115,865 individuals available for analysis. Linear 
regression models implemented in R were used to test the association between AUDIT score 
and rs2513280 genotype and the interaction effects of anxiety and sex. With AUDIT score as 
the outcome variable we fitted rs2513280, sex and anxiety as main effects and then a three-
way interaction term of sex*anxiety*rs2513280. We also used twenty principal components as 
covariates to adjust for potential population stratification in the UK Biobank sample.  
rs2513280 genotype was modelled as a continuous variable (coded 0,1,2 corresponding to the 
number of C alleles carried).  
Generation of gRNA molecules by a novel annealed oligo template (AOT) method. 
Single guide RNA (sgRNA) molecules were designed to disrupt the GAL5.1 enhancer using 
the optimised CRISPR design tool (http://CRISPR.mit.edu/). sgRNA template was produced by 
annealing oligonucleotides to produce two different DNA templates as previously described 17 
that included a T7 polymerase binding site and predicted guide sequence target sites 
spanning the most conserved central region of the mGAL5.1 enhancer (5’sgRNA; CTC CCT 
GGA GCA ATA TGA AG and 3’sgRNA; CCC GCT TTC ATG GCT CCC AA). These 
oligonucleotides were annealed and amplified using PCR to produce a 122 bp double strand 
sgRNA template. 100 ng of this template was used to produce sgRNA using a mMESSAGE 
mMACHINE T7 in-vitro transcription kit (Ambion) described in the manufacturer’s instructions 
and purified using a Megaclear kit (Ambion) with modifications as previously described 18.  
Production of genome edited mice.  sgRNA molecules were microinjected at a 
concentration 10 ng/µl each into the cytoplasm of 1-cell C57BL/6 embryos (Harlan, UK) as 
described 18 together with 10 ng/µl CAS9 mRNA (Life Technologies). Two-cell embryos were 
introduced into host CD1 mothers using oviduct transfer as previously described 19 and 
correctly targeted offspring were determined by PCR of earclip DNA using the following 
flanking primers (mGAL5for; AGTTAGGGCGCACACATCAA, mGAL5rev; CCGTGACTAACG 
GCTAATGC). These PCR products were purified and sequenced. Sequencing data was then 
analysed using the Blat tool (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC187518/  “BLAST-
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like alignment tool”) of the UCSC browser to compare the sequence of the PCR product 
against that of the mouse genome (Fig 1F and G). 
In-situ Hybridisation. Radioactive in-situ hybridisation was carried out on 10μm brain 
sections derived from wild type mice using radiolabelled Gal or Early Growth Response gene 1 
(EGR1 or Zif268)) antisense RNA probes as previously described 20.  
Quantitative reverse transcriptase-PCR. Brain tissues were dissected as described 
(hippocampus and cortex; 21; hypothalamus22 and Amygdala23  and supplementary data 7) out 
of the whole brain and snap frozen on dry ice. Total RNA was extracted using the isolate II 
RNA minikit (Bioline).  Quantitative reverse transcriptase-PCR (QrtPCR) to determine mRNA 
expression levels of genes flanking mGAL5.1 (Low-density lipoprotein receptor-related protein 
5 (Lrp5), Protein Phosphatase 6 Regulatory Subunit 3 (Ppp6r3), Gal, Tesmin (Mlt5) and 
carnitine palmitoyltransferase 1A (Cpt1a) was undertaken using gene specific primers (See 
table 1 in supplementary data) on derived cDNA using mouse Qrt-PCR primers as previously 
described 24, 25 using a Roche Light Cycler 480 with Roche SYBR green. All QrtPCR analyses 
were normalised using mouse primers specific to the Non-POU Domain Containing Octamer 
Binding protein (Nono) housekeeping gene that gave the most stable expression in all 
neuronal tissues analysed compared to βactin, Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) or Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) 
genes. 
Animal studies. All animal studies were performed in accordance with UK Home Office 
guidelines. All mice used were sex and age matched (12-18 weeks) littermates except where 
indicated. Phenotypic analysis of the morphology, general health, motility, behaviour and 
breeding success of these animals was also carried out. All animals were assigned random 
numbers after genotyping so that none of the operators knew the genotypes of the animals 
prior to testing.  
8 
 
Alcohol preference studies Preference for ethanol was tested by allowing animals free 
access to a choice of 10% v/v ethanol or pure water intake using a two-bottle choice protocol 
as described previously 26. Mice were housed in TSE home cage systems (TSE) that record 
liquid intake automatically.  Initially mice were group housed (~4 / cage) and habituated for 5 
days to allow for adaptation to the monitored bottles. The mice were subsequently singly 
housed and habituated for a further 5 days prior to introduction of a second bottle containing 
the ethanol solution. Intake of both water and 10% ethanol solution were monitored at 30 min 
intervals over the course of the trial and recorded by TSE PhenoMaster Software (TSE-
systems). Bottles were regularly swapped to reduce positional effects on consumption. A taste 
preference test to identify differences in sweet and bitter taste preferences between wild type 
and GAL5.1KO animals was performed by offering animals a choice of water, water and 
saccharine (2mM) or water and quinine (0.3mM; supplementary data 5) 27. 
Open Field test (OFT). The OFT consisted of a square 30 cm (30 cm high) PVC open 
field arena positioned on a white base with overhead lighting applying 100 lx at the base28. 
Animals were transported individually to the testing room, habituated (30 mins) and released 
into the corner of the arena. Ambulatory activity was recorded in the open field for 300 s using 
an overhead video camera and the ANY-maze tracking software (Stoelting Europe). The 
software was used to define two zones in the open field at approximately 35 cm2 centre zone 
and 30 cm2 peripheral zone. Distance travelled, mean speed, Peripheral zone and no. centre 
entries, were determined by the software.  
Elevated zero maze (EZM). The EZM consists of an annular dark-gray platform (60 cm in 
diameter) constructed of opaque Perspex divided into four equal quadrants. Two opposite 
quadrants were “open”; the remaining two “closed” quadrants were surrounded by 16 cm high 
dark, opaque black walls. Quadrant lanes were 5 cm in width. Overhead lighting applying 100 
lx at the level of the maze. The movement of animals was tracked using a camera and ANY-
maze tracking software. Distance travelled, average speed, number of crossings between 
light/dark zones and freezing episodes, freezing time and freezing latency were recorded. 
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Novel suppressed feeding test (NSFT). The NSFT assesses levels of anxiety by 
measuring the latency of a fasted animal to approach and eat a familiar food in an unfamiliar 
environment. The NSFT resembles the OFT except that animals are fasted for 16 hours before 
the test and the animal is then placed in the open field apparatus with a pellet of food fixed to a 
disc of filter paper and placed in the centre of the cage. The latency period between placing 
the animal in the test and first bite of the food pellet was recorded. The numbers of lines 
crossing and the speed and distance covered by the animal during the test was also recorded. 
Marble burying test (MBT). The MBT consisted of a a “Eurostandard type iv s” 
(Techiplast) cage (480 x 375 x 210 mm) cage with 5cm depth of wood chip bedding onto 
which 20 evenly spaced marbles were placed. Animals were then placed in the cage and the 
numbers of marbles buried after 30 minutes were recorded. 
GAL5.1 Deletion and expression constructs. Primers were designed that flanked the 
conserved putative EGR1 binding site within the GAL5.1 enhancer (ARM212-D2F; ATA GAT 
TTC AGA AAA GAA AGC TT,  ARM213-D2R; TAA AAT GAC TGG CAT TAG AGC TC -3’). 
These were used in a PCR reaction with Q5 Hi-Fidelity polymerase (NEB, USA) in 
combination with the pLuc-GAL5.1 reporter construct previously described 8 as template to 
produce pLuc-GAL∆EGR. The PCR product was ligated with T4 ligase prior to transformation 
into competent cells (Stratagene). The plasmid was sequenced to validate the removal of the 
putative EGR1 binding site. Expression constructs (pcDNA-EGR1 and pcDNA-PKCε) were 
obtained from Addgene. 
Cell culture and transfection studies. SH-SY5Y cells (94030304, ECAC) were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM; Gibco,) containing low Glucose (5.5mM), L-
Glutamine (4mM), and Sodium Pyruvate (1mM). Medium was previously supplemented with 
10% (v/v) heat-inactivated Foetal Bovine Serum (FBS; Gibco) and 1% (v/v) Penicillin-
Streptomycin (Pen-Strep; Gibco, UK). Cells were transfected with luciferase reporter plasmids 
DNA described above using jetPRIME as per manufacturer’s instruction (Polyplus Illkirch). 
Assays were normalised by co-tranfected with renilla luciferase plasmid pGL4.74 (Promega) or 
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by assaying total protein in extract.  After transfection, cells were treated with phorbol 12-
myristate 13-acetate (PMA; 100nM in DMSO) or DMSO or PKC antagonist (GF10930X; 
Tocris) for 24 hours following which cells were lysed for dual luciferase analysis as per 
manufacturer’s instructions (Promega UK). 
Data analysis. From in-vivo studies we calculated that a minimum of 6-12 animals per 
group would enable detection of a 25% difference between different parameters (ethanol 
intake, anxiety-like behaviour) with 80% power using one-way ANOVA and/or general linear 
modelling. Statistical significance of data sets was analysed using either one-way analysis of 
variance (ANOVA) analysis with Bonferroni post hoc tests or using two tailed unpaired 
parametric Student t-test as indicated using GraphPad PRISM version 5.02 (GraphPad 
Software, La Jolla, CA, USA). 
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Results. 
The G-allele of rs2513280 associates with increased alcohol consumption in men 
when stratified against anxiety. In order to test the validity of two previous association 
analyses9, 10 we investigated whether there was an association between allelic variants of the 
GAL5.1 enhancer and increased alcohol intake in a much larger cohort comprising 345,140 
individuals (UK Biobank; 183,921 females and 161,219 males). In the total sample a marginal 
association between the G allele of rs2513280 (a proxy for both loci in perfect LD) and 
increased weekly alcohol intake in women was identified (b=0.008, s.e.=0.004, p=0.0463).  
When analysing males and females separately, the association between male alcohol intake 
and rs2513280 became non-significant (b=0.004, s.e.=0.006, p=0.478); however, in females 
the association was stronger and remained significant (b=0.012, s.e.=0.006, p=0.037).  
Because of the known link between anxiety and alcohol abuse in men29 we further 
investigated the interaction of these variables with respect to rs2513280 using a subset of the 
UK Biobank that also contained information relating to anxiety15. DNA was derived from blood 
and there were 64,465 females and 51,539 males in the anxiety cohort.  There was an effect 
of male sex on AUDIT score with males having significantly higher AUDIT scores than females 
(Table 1, b=0.34, S.E.=0.005, p < 2 x 10-16). Individuals with higher levels of self-reported 
anxiety also had significantly higher AUDIT scores although there was no main effect of the 
rs2513280 polymorphism (Table 1). No significant interactions were detected between sex 
and rs2153280 or anxiety and rs2513280 (Table 1).  However, anxious males reported 
significantly higher AUDIT scores (p=0.0007) if they carried the major allele at the rs2153280 
locus (Table 1 and supplementary Fig 2A).  Comparisons of analyses carried out using 
AUDIT-T, AUDIT-C and AUDIT-P are also shown in for comparison (supplementary data 
figure 2A.) 
The GAL5.1 enhancer supports reporter gene expression in specific regions of the 
brain including the hypothalamus and amygdala. To further analyse the tissue specific 
activity of hGAL5.1 we cloned the human GAL5.1 enhancer next to a LacZ reporter (hGAL5.1-
LacZ) and used this construct to generate transgenic reporter mouse lines as previously 
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described8. Closer analysis of brain sections derived from these mouse lines identified 
expression of the LacZ reporter in cells of the periventricular (PVN), dorsomedial (DMH) and 
arcuate nuclei (ARC; Fig 1B) of the hypothalamus as well as the medial nucleus of the 
amygdala (MeA; Fig 1C) that corresponded to the expression patterns of the endogenous wild 
type mouse Gal gene both at a tissue-specific (Fig 1A and C) and cellular level 8.  
Rapid and accurate disruption of mGAL5.1 in mice was achieved using 
CRISPR/CAS9.  To determine a functional role for GAL5.1 in-vivo we chose two target 
sequences (5’sgRNA and 3’sgRNA) that flanked the most highly conserved region of the 
mouse GAL5.1 homolog (mGAL5.1; chr19:3440931-3441185; Fig 1E) and used our previously 
described AOT method to produce sgRNAs that, when injected into mouse embryos, would 
induce a disruptive 230 bp deletion in mGAL5.117.  We microinjected AOT derived sgRNA and 
CAS9 mRNA into the cytoplasm of 90 1-cell C57BL/6 mouse embryos. 90% of these embryos 
survived and were oviduct transferred into host female CD1 mice to generate a homozygous 
female and two heterozygous male mice that contained identical deletions within GAL5.1 
following analysis by PCR and electrophoresis (mGAL5.1KO; Fig 1F and G) without any 
evidence of off-target effects 30. These mice were crossed onto wildtype C57BL/6 mice to 
produce a colony of male and female mGAL5.1KO heterozygote mice that were subsequently 
used to produce the age/sex and homozygote wildtype and mGAL5.1KO littermate mice 
(determined by PCR of earclip DNA from each animal prior to testing) used in the current 
study.  We also carried out an extensive phenotypical analysis of GAL5.1KO animals based on 
previous criteria 31 and found no significant observable change in phenotypic or health status 
as a result of the genetic modification and GAL5.1KO mice were healthy and viable (see 
supplementary data 3 and 4). 
Disruption of mGAL5.1 reduces expression of GAL in amygdala, hypothalamus and 
hippocampus but does not affect the expression of flanking genes in hypothalamus. We 
compared the expression of the Gal gene in mRNA derived from various regions of the brain in 
wild type and mGAL5.1KO mice. Expression of Gal mRNA was strongest in the hypothalamus 
and the amygdala with some evidence of Gal mRNA expression in hippocampus and cortex 
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(Fig 2A and B). We observed that expression of Gal was greatly reduced in all these tissues 
in mGAL5.1KO animals (Fig 2A and B) suggesting that mGAL5.1 is essential for a significant 
proportion of Gal expression in these tissues. 
We also analysed the influence of mGAL5.1 disruption on the expression of Gal and four 
other genes flanking the Gal locus in the hypothalamus namely Lrp5, Ppp6r3 (5’ of mGAL5.1) 
Mtl5 and Cpt1a (3’of mGAL5.1) that are all maintained in the same synteny block32 in both 
humans and mice spanning 536kb in humans and 379kb in mice (Fig 2C). Although we found 
strong down regulation of the Gal gene we saw no significant change of expression in any of 
the flanking genes suggesting a lack of requirement for mGAL5.1 for expression of these 
genes in the hypothalamus (Fig 2D)33. 
mGAL5.1KO animals exhibit a decreased preference for ethanol.  
Because the GAL gene has been shown to control intake of alcohol2, 3 and that a 
polymorphism within the GAL5.1 enhancer was associated with increased alcohol intake in 
women and in men who also reporting anxiety we tested the hypothesis that disruption of the 
mGAL5.1 enhancer would reduce preference for ethanol in mice. We provided ad-libitum 
access to bottles containing either water or water and 10% ethanol (both bottles sweetened 
with 0.05% saccharine) to singly housed mGAL5.1KO and WT male and female littermates 
mice and recorded intake for 10 days (Fig 3A and B).  Both male and female mGAL5.1KO 
mice consumed significantly less 10% ethanol than wild type animals when given the choice 
(Fig 3A) and no significant difference in intake was detected between sexes. On average, wild 
type mice drank the equivalent of 3.7 grams of pure ethanol per kg per mouse per day 
whereas the GAL5.1KO mice only drank 1.1 grams (Fig 3B). To rule out the possibility that 
animals lacking the GAL5.1 enhancer had an altered preference for sweet or bitter tastes, that 
would skew the alcohol preference tests, we also carried out a taste preference test by offering 
wild type of GAL5.1KO animals a choice of water or water sweetened with saccharine or made 
bitter with quinine. We observed no evidence of altered preferences for bitter or sweet tastes 
as a result of GAL5.1 disruption (Supplementary figure 5). 
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mGAL5.1KO mice exhibit an increase in marble burying and decreased latency to 
feed in the NSFT. Both the MBT and the NSFT have been widely used to assess levels of 
anxiety-like behaviour in mice. Using the MBT we observed that both male and female 
mGAL5.1KO animals buried significantly more marbles within the 30-minute period of the test 
than did their wild type littermates (supplementary data 6) consistent with reduced anxiety. In 
addition, we observed decreased latency in the time taken for fasted mGAL5.1KO animals to 
take their first bite of the food pellet within a novel environment although this only achieved 
significance in the mGAL5.1KO males (Fig 3C). Intriguingly, both males and female 
mGAL5.1KO mice demonstrated a significant increase in both numbers of line crossing 
between the peripheral zone and the centre zone (Fig 3D) as well as the distance travelled 
(Fig 3E) within the arena during the duration of the test.   
Male mGAL5.1KO mice demonstrate reduced anxiety-like behaviour in the OFT and 
the EZM tests. The OFT has been previously used as a test for anxiety-like behaviour 34. We 
first noticed a significant increase in the amount of centre entries displayed by male 
mGAL5.1KO mice compared to litter matched wild type animals (Fig 4A). We also noted an 
increase in the proportion of the distance moved by GAL5.1KO mice (Fig 4B) as well as the 
proportion of time spent within the centre zones (Fig 4C). No significant difference in these 
behaviours was observed between female WT(fWT) and mGAL5.1KO (fKO) mice exposed to 
the OFT (Figs 4A-C)  
The EZM measures the innate fear of small rodents for open areas against the security of 
a closed area and is a refinement of the elevated plus maze 35. We observed that male mice 
placed into the EZM displayed a significantly greater percentage of their time within the open 
quadrants of the maze (Fig 4D). In addition, male mice travelled a greater distance (Fig 4E) at 
a marginally faster speed (Fig 4F) whilst crossing between the light and dark sides with 
greater frequency (Fig 4G). Much of the difference in overall speed and distance between WT 
and KO males were attributable to the observed reduction in freezing behaviour (frequency 
and latency) displayed by male mGAL5.1KO animals compared to wild type animals (Figs 4H 
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and I). No significant difference in anxiety-like behaviour was observed between wild type and 
GAL5.1KO female mice exposed to the EZM (Figs 4D-I). 
EGR1 interaction and modulation of the PKC response varies with GAL5.1 
genotype. To identify transcription factors that were involved in modulating GAL5.1 activity we 
undertook a bioinformatic analysis of the GAL5.1 enhancer using ENCODE data on the UCSC 
browser (Fig 5A). ENCODE identified highly conserved regions of GAL5.1 that were sensitive 
to DNAse1 digestion; a diagnostic of open, transcriptionally active chromatin, in several 
different cell lines (Fig 5Ai and B). This analysis also highlighted the presence of a highly 
conserved binding consensus of EGR transcription factors that lay within the DNAseI 
hypersensitive region (Fig 5Aii and B) in a highly conserved region of GAL5.1 (Fig 5Aiii and 
B). Furthermore, EGR1 (AKA Zif268) is expressed in the PVN (Fig 5C) and is up-regulated in 
the ARC in response to anorexia stimulated melanocortin signalling36. We produced luciferase 
reporter constructs containing the GAL5.1(GG) enhancer and a derivative of GAL5.1(GG) 
lacking the conserved EGR binding site (pLuc-∆EGR1). These were transfected into a 
neuroblastoma cell line (SH-SY5Y) in the presence of an empty expression vector (pcDNA3) 
or an expression vector expressing the EGR1 protein (pcDNA3-EGR1, Addgene). These 
experiments demonstrate that expression the EGR1 transcription factor in neuroblastoma cells 
significantly increased GAL5.1 activity and that the putative EGR1 binding site identified in 
GAL5.1 is critical to this interaction (Fig 5D). In order to confirm that the effects of PMA on 
GAL5.1, as previously reported 8, were PKC specific we tested the effects of different 
concentrations of the PKC antagonist GF10930X on the PMA driven up-regulation of the 
GAL5.1(GG) genotype. We showed that PMA induction was significantly reduced following co-
treatment with 1000nM concentration of the PKC antagonist (Fig 5E). Further analysis 
comparing the effects of EGR1 expression on the GAL5.1(GG) and GAL5.1(CA) genotype 
reporter constructs showed that, whilst the GG genotype responded strongly to EGR1 
expression in SH-SY5Y cells, the CA genotype did not (Fig 5F). In addition, the PMA induced 
response of the CA genotype was blunted in comparison to the GG genotype (Fig 5F).  
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Discussion. 
Understanding the processes that modulate preference for ethanol is particularly pressing 
in men where 7.6% of all male deaths globally can be attributed to alcohol abuse through 
accidental death, cardiovascular disease, liver damage and cancer 37 . Anxiety remains one of 
the most frequent co-morbidities associated with excessive alcohol intake38 and identifying and 
understanding the genomic mechanisms that link anxiety with excessive alcohol intake will be 
an important component in understanding and combating alcohol abuse29.  A previous 
genotype analysis of polymorphisms around the GAL gene locus in two different populations 
(Finns and Plains Native Americans) identified robust associations with alcohol intake and 
specific genotypes 5. Intriguingly, this study also uncovered evidence of a sex specific role for 
anxiety in modulating alcohol intake 5. Unfortunately, the authors were unable to identify a 
molecular mechanism that could account for their findings. The current study explored the 
problem from the initial standpoint of functionality. This was achieved by analysing the effects 
of polymorphisms known to change the activity of the highly conserved GAL5.1 enhancer 
sequence found 42kb from the GAL gene 8.  
We began our analysis of a possible role for the GAL5.1 enhancer in alcohol intake by 
interrogating the UK Biobank cohort to determine the validity of previous conflicting smaller 
scale association studies 9, 10. Our analysis supported observations by Nikolova et al (2013) 
who reported an association between the G-allele of GAL5.1 and increased alcohol intake in 
women 9 but not in men. Because anxiety has been identified as an important variable 
influencing alcohol intake in humans1 and had also been identified as being an important 
variable in modulating the role of the GAL gene in alcohol intake5, we carried out a deeper 
analysis of the rs2513280 polymorphism UK biobank by stratifying alcohol intake with anxiety. 
We were intrigued to find a highly significant association (p=0.0007) between reported anxiety 
and drinking behaviour in men with the GG genotype that was not observed in women.  
 To further explore the role of GAL5.1 in ethanol intake we disrupted GAL5.1 in mice using 
CRISPR/CAS9 genome editing. Using QrtPCR of different brain regions of GAL5.1 knock out 
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mice we found that disruption of GAL5.1 had a significant impact on the expression of Gal 
mRNA expression in hypothalamus, amygdala, hippocampus and cortex consistent with a 
requirement for GAL5.1 for appropriate expression of Gal in these brain regions.  Moreover, 
analysis of gene expression of four other flanking genes suggested that GAL5.1 is specific in 
its modulation of the expression of the Gal gene in the hypothalamus; although we are unable 
to rule out a possible role for GAL5.1 in regulating the expression of these genes in other 
tissues or the regulation of more remote genes. However, the most striking outcome of the 
current study was the observation that CRISPR/CAS9 disruption of GAL5.1 significantly 
reduced preference for ethanol in both male and female mice demonstrating a key role for 
GAL5.1 in ethanol preference and intake. These observations contrasted with previously 
observations of the effects of Gal gene knockouts where reduction of ethanol intake primarily 
observed in female mice 39. These observed differences might be partly explained by 
differences in the genetic background of the GAL5.1KO (C57BL/6Harlan) and the GAL gene 
deletion mice(129Ola/Hsd)40. There is also a likelihood that, because disruption of the GAL5.1 
enhancer does not remove all expression of the Gal gene, many of the sex specific differences 
observed may also be explained by the presence of residual sex-specific Gal gene expression 
in different parts of the brain. A third likelihood could reflect differences in the genetic loci 
targeted such that the Gal gene and the GAL5.1 enhancer loci in mice are 26kb apart and 
represent regions of the genome subject to different genetic and epigenetic influences. A 
fourth explanation, that we cannot rule out, is the possibility that GAL5.1 also controls the 
expression of other more remote genes involved in ethanol intake whose interactions have yet 
to be characterised. 
Anxiety is one of the most frequently reported co-morbidities of alcohol abuse 1, 38. It is 
intriguing, therefore, that genetic analyses of different genotypes within the GAL locus 
succeeded in identifying an association with excess alcohol intake that was influenced by sex 
and anxiety5. These observations are supported by our current analysis of the UK biobank 
human cohort that also identified a significant association of a GAL5.1 enhancer polymorphism 
with alcohol abuse when stratified against sex and anxiety. We therefore asked whether our 
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CRISPR/Cas9 knockout of GAL5.1 altered anxiety-like behaviour in mice and whether there 
was evidence of the apparent sexual dimorphisms observed in previous studies5 and in our UK 
Biobank analysis. Our initial analysis of mGAL5.1KO mice using the MBT demonstrated that 
removal of mGAL5.1 increased the tendency of both male and female mice lacking GAL5.1 to 
bury marbles; an accepted diagnostic of anxiety-like behaviour but also of obsessive 
compulsive disorder41. Interestingly, we also observed greatly increased numbers of line 
crossing as well as more distance travelled by both sexes of mGAL5.1 mice exposed the 
NSFT (AKA hyponeophagia) which suggests that GAL5.1 may play a role in exploratory 
foraging behaviour42.  However, we only observed a decrease in feeding latency in the NSFT 
in males lacking GAL5.1 which suggested the possibility that some aspects of anxiety-like 
behaviour in mice are modulated by GAL5.1 in a sex specific manner. This hypothesis was 
further reinforced by observations of the behaviours of mGAL5.1KO mice exposed to the OFT 
who spent proportionately more time in the centre of the OFT and proportionally moved a 
further distance. Further support for this observation came from the EZM whereby male 
mGAL5.1KO mice spent a significantly larger proportion of their time in the open quadrants of 
the EZM. Notably, these mice also displayed a reduced number of freezing episodes providing 
further evidence of a reduced fear response 43. The observed sex specific reductions in 
anxiety demonstrated by mGAL5.1KO mice in the NSFT, the OFT and the EZM are consistent 
with the sexual dimorphism observed in our stratified analysis of the UK biobank cohort and in 
previous analysis of polymorphisms around the GAL gene5. It is obvious that many more 
behavioural aspects of anxiety, such as social interaction, stress and conditioned fear 
response, need to be explored in these animals to better comprehend the specific role played 
by GAL5.1 in anxiety-related behaviour. Moreover, critics of the MBT and the NSFT correctly 
point out that the results of these tests may be skewed by an increase in compulsive 
behaviour and appetite respectively. Nevertheless, when the results of all our behavioural 
tests are considered together, our study suggests that the GAL5.1 enhancer plays an 
important role in modulating significant sex specific aspects of anxiety-like behaviour and 
ethanol intake in both mice and humans.  
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Even though we have identified phenotypic differences in the human population reflecting 
findings within our mouse models, we are also aware that the changes in our human cohort (2 
base pair change in hGAL5.1) are not strictly equivalent to those induced in our mouse models 
(230bp deletion in mGAL5.1) and it would be expected that our mouse deletion would produce 
a more extreme phenotype than that seen in humans. Indeed, we recognise that only by 
recreating both human the CA and GG genotypes in mice and comparing their phenotypic 
effects might a truly equivalent comparison be made. Nevertheless, our current study 
represents a major step towards defining a better understanding the role of GAL5.1 in 
mammalian ethanol intake and mood and defines a clearer path to identification and analysis 
of other conserved enhancers involved in modulating health and disease. 
Closer analysis of the GAL5.1 sequence using a combination of bioinformatics and cell 
co-transfection studies suggested a functional interaction between the EGR1 transcription 
factor and a highly conserved EGR binding site within a highly conserved region of GAL5.1.  
EGR1 has a high affinity for DNA and is known to be able to bind DNA even when methylated 
44. Nevertheless, the literature describing the effects of ethanol on EGR1 expression and 
activity could be clearer. For example, it was reported that EGR1 binding to DNA was reduced 
following ethanol exposure45. In contrast, more recent reports suggest that expression of 
EGR1 in the brain was increased in animals exposed to ethanol 46, 47. From a mechanistic 
perspective it is possible that EGR1 acts as a “pioneer factor” by being one of the first 
transcription factors that bind to the closed and methylated GAL5.1 locus thus activating its 
tissue specific activity. Interestingly, we observed that the CA allele of GAL5.1 did not respond 
to EGR1 expression and its PKC response was blunted. This is an interesting observation as 
the EGR1 binding site is 100bp from the closest of the SNPs within GAL5.1 (rs2513281). We 
propose that the EGR1 protein forms part of a larger protein complex that interacts across the 
whole GAL5.1 enhancer. It is therefore possible that EGR1 binding and GAL5.1 function is 
dependent on binding of another, as yet unidentified, protein whose binding is interrupted by 
one of the allelic variants of GAL5.1 thus affecting EGR1 binding.  
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We also explored the possible interaction of PKC pathways in the activity of the GAL5.1 
enhancer. Previous analysis demonstrated that the non-specific PKC agonist PMA increased 
the activity of GAL5.1 in primary hypothalamic cells8. In the current study we support these 
previous studies by showing that antagonism of PKC decreases the effects of PMA on GAL5.1 
activity. We have also expanded our analysis to show that upregulation of PKA pathways 
increase the effects of EGR1 expression on the activity of the GG genotype of GAL5.1 but not 
in the less active and protective CA genotype; an observation that may allow us to design 
personalised therapies. Our best candidate for the PKC isoform responsible for modulating 
GAL5.1 activity, and to which we may target future drug therapies, is PKC epsilon (PKCε) 
which is expressed in the amygdala and PVN 48, 49. Moreover, genetic deletion of PKCε 
reduces ethanol intake 48 and anxiety like behaviour in mice 49. Future work will focus on 
determining the possible relevance of this isoform in the activity of the GAL5.1 enhancer and 
determining whether antagonism of this, and other PKC isoforms, may reduce the activity of 
the GG genotype to that of the protective CA genotype thus opening the possibility of 
developing a novel personalised anxiolytic therapy that reduces ethanol intake in men. 
Conclusion. To the best of our knowledge, this is the first time that the unique 
combination of techniques used in our study; comparative genomics, CRISPR/CAS9 genome 
editing and behavioural analysis in mouse models, have been used to establish a functional 
role for a tissue-specific enhancer region in alcohol selection and mood in living animals. This 
study is given even greater impact by our analysis of the UK biobank cohort that demonstrates 
a link between increased alcohol intake and anxiety in males paralleling that seen in our 
CRISPR derived models. The current study also goes some way to addressing the age-old 
question of whether alcohol abuse causes anxiety (substance-induced anxiety model), or 
whether alcohol use is caused by anxiety (self-medication model), by providing supporting 
evidence that a common mechanism contributes to both behaviours (common-factor model) 1, 
38.   
Placing the current study within the wider context of understanding the mechanistic basis 
of complex human disease it is clear that an important step has been made in bridging the gap 
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between association analyses and mechanism especially in light of the fact that the majority of 
associated SNPs generated by GWAS are in the non-coding genome50. Although histone 
markers (e.g. H3K4me1, H3K27ac etc) and GWAS are currently the favoured techniques used 
to identify candidate regulatory regions affected by disease associated polymorphic variation 
on a genome wide level the current study serves to emphasise that there is also merit in the 
use of comparative genomics and functional characterisation of the cell specific activity of 
putative regulatory elements using CRISPR genome editing in cell based and whole animal 
systems.  
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Figure Legends. 
Figure 1A and C, Dark field images of 10µm sections through (A) the hypothalamic 
region and (C) the amygdala region of wildtype mouse probed with S35 labelled Gal antisense 
RNA. (B and D) vibratome sections through (B) the hypothalamic and (D) the amygdala 
regions of mice transgenic for the human GAL5.1-LacZ reporter construct (hGAL5.1-LacZ) 
demonstrating LacZ expression in cells of the periventricular (PVN) Dorsomedial (DMH) and 
arcuate (ARC) nuclei (V3, 3rd ventricle) of the hypothalamus (A and B) and the (MeA) medial 
amygdaloid nucleus of the amygdala (C and D).  E. Comparative genomic analysis of 
sequence flanking the human GAL locus demonstrating the position (numbered black scale 
bar at top), distance (blue arrows) and depth of conservation (green peaks) of the human 
GAL5.1 locus (red box) relative to the GAL gene (blue box). F and G. DNA sequencing data 
derived from PCR products of ear clip DNA derived from a homozygote GAL5.1 KO mouse 
(thick black bar labelled GAL5.1KO58) and blasted against the mouse genome (UCSC 
browser). The sequence disruption produced by introduction of CAS9/sgRNA is displayed 
relative to the PAM sequence (green box) of each sgRNA demonstrates the accuracy of (F) 
5sgRNA and (G) 3sgRNA relative to the missing regions of the genome (thin black lines and 
chevrons). Electrophoresis gels demonstrating the difference in PCR product sizes are 
published elsewhere 30. 
Figure 2. A. GAL5.1 specifically regulates expression of the Gal gene in the 
hypothalamus and amygdala but not flanking genes. A. Bar graph showing relative levels 
of Gal expression as measured by QrtPCR in different brain areas (Hypo, hypothalamus; 
Amyg, amygdala; Hipp, hippocampus, Cort; cortex) in wild type (WT) and mGAL5.1KO 
animals. B. Scatterplots demonstrating QrtPCR analysis of Gal mRNA expression in RNA 
derived from hypothalamus, amygdala, hippocampus and cortex on total RNA derived from 
wild type (WT) or GAL5.1 knockout (mGAL5.1KO) animals(**;p<0.01). C. Scale diagram 
(UCSC genome browser) representing genes surrounding the mGAL5.1 enhancer (red box). 
Exons are displayed as thick blue lines and introns by thin blue lines punctuated by chevrons 
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denoting the direction of transcription. Genomic coordinates on mouse chromosome 19 are 
highlighted by black perpendicular lines. D. Scatterplots showing QrtPCR analysis of cDNA 
derived from total hypothalamic RNA comparing mRNA expression of Lrp5, Ppp6r3, Gal, Mtl5 
and Cpt1A  in wild type and GAL5.1KO animals normalised against the expression of the 
Nono gene (y-axis). (****, p<0.001, n.s., no significance). 
Figure 3. GAL5.1 disruption decreases ethanol intake and modulates anxiety-like 
behaviour in the novelty suppressed feeding test. A. Scatterplot demonstrating the 
percentage intake of 10% ethanol in male and female mGAL5.1KO (KOe) and wild type litter 
mates (WTe) compared to water alone in mGAL5.1KO mice (KOw) and wild type littermates 
(WTw; error bars, SEM, n=12-14; ****, p<0.0001; F=30.83; d.f.=3) over the 10 days of the 
experiment.  B. Scatterplot demonstrating ethanol intake in mGAL5.1KO (KO) male and 
female mice compared to wild type littermates (WT) expressed as grams of ethanol consumed 
per kilogram of mouse per day (error bars= SEM; n=12-14, ****, p<0.0001; t=5.918; d.f.=24).  
C-E. Scatter plots demonstrating latency to feed (C; F=4.617; d.f.= 3), number of line 
crossings (D; F=12.46; d.f.=3 ) and distance travelled (E; F=5.965; d.f.=3) as analysed using 
the novelty suppressed feeding test (NSFT; n=7; error bars= SEM; n.s., not significant; *, p 
=0.05;  **, p<0.01; ***, p<0.005; ****, p<0.0001). 
Figure 4. mGAL5.1 deletion affects sex specific aspects of anxiety-like behaviour in 
the open field test and the elevated zero maze. A-C. Scatterplots demonstrating increased 
number of centre entries (A; F=2.290, d.f.=3), percentage distance moved in the centre zone 
(B; F=2.583, d.f.=3) and the percentage of time in the centre zone (C; F=2.176, d.f.=3) of male 
GAL5.1KO mice (mKO) compared to male wild type mice (mWT) using the open field test 
(OFT). Female GAL5.1KO mice (fKO) and wild type mice (fWT) demonstrated no significant 
behavioural difference in the OFT(A-C). D-I. Scatterplots demonstrating changes in the time 
spent in the open quadrants of the elevated zero maze (EZM) (D; F=25.80, d.f.=3), the 
distance travelled (E; F=3.605, d.f.=3) the average speed (F; F=3.846, d.f.=3), the numbers of 
crossings between the light and dark zones (G; F=6.498, d.f.=3), the number of freezing 
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episodes (H; F=6.088; d.f.=3) and the time until the first freezing event (I; f=16.48; d.f.=3) by 
mKO and mWT animals. Female GAL5.1KO mice (fKO) and wild type mice (fWT) 
demonstrated no significant behavioural difference (D-I) in the EZM. (OFT, n=10-12; EZM, 
n=7; n.s., not significant; *, p =0.05;  **, p<0.01; ***, p<0.005; ****, p<0.0001). 
Figure 5. EGR1 interaction and modulation of the PKC response varies with GAL5.1 
genotype. A. UCSC browser output of 800bp surrounding the GAL5.1 enhancer showing 
regions of DNAseI hypersensitivity (Ai; filled grey bars), conserved transcription factor binding 
consensus sequences (Aii; filled black boxes) and degree (Aiii; blue peaks) and depth (Aiii; 
green lines) of sequence conservation. B. UCSC output showing hypersensitivity sites (grey 
bars), conserved EGR1 consensus sequences (black bars) and degrees of conservation (Blue 
peaks). Multiz alignment of conserved consensus sequences demonstrates degrees of 
conservation at the base pair level where dots represent identical base pair to human. C. In-
situ hybridisation demonstrating the expression of Egr1 mRNA within the periventricular 
nucleus (PVN) of the mouse hypothalamus. D. A scatterplot demonstrating dual luciferase 
data derived from SH-SY5Y cells transfected with different combinations of pcDNA3 (empty 
expression vector), pLuc (empty reporter vector), pcDNA-EGR1 (Expression vector expressing 
EGR1 transcription factor), pLuc-GAL5.1 (reporter vector containing the GAL5.1 enhancer), 
pLuc-Gal∆EGR (reporter construct containing the GAL5.1 enhancer lacking the EGR binding 
consensus shown in B (n=5-6; F=60.47; d.f.=5).  E. A scatterplot demonstrating the effects of 
different concentration of the PKC antagonist GF10930X on the PMA stimulated activity of the 
pLuc-GAL5.1 plasmid (GAL5.1) compared to the empty luciferase vector (pLuc; n=6, **, 
p<0.01; ***, p<0.005; F=37.62; d.f.=7). F. A Scatterplot comparing the effects of co-
transfection of an EGR1 expressing plasmid (pcDNA-EGR1) and/or PMA treatment on cells 
co-transfected with a renilla luciferase expressing plasmid and a firefly luciferase reporter 
constructs containing either the GG or CA genotypes of the GAL5.1 enhancer (n=4, ns; no 
significance, ***;p<0.005;  ****;p<0.001; F=54.91; d.f.=7).  
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Table 1.  Interactions between different variables after analysis of the UK Biobank 
demonstrating a stronger than expected interaction (p=0.0007) between anxiety, sex, allelic 
variation at the rs2513280 locus and alcohol intake as measured by AUDIT score. 
 





Variable  Estimate  S.E. P-value 
Sex (male) 0.34 0.005 <2x10-16 
rs2513280 0.003 0.006 0.58 
Anxiety  0.03 0.006 <3.7x10-6 
Sex(male)*anxiety -0.005 0.01 0.60 
Sex(male) *rs2513280 -0.01 0.009 0.12 
Anxiety*rs2513280 -0.02 0.01 0.10 
Sex(male)*anxiety*rs2513280 0.06 0.02 0.0007 
Table 1.  Interactions between different variables after analysis of the UK Biobank 
demonstrating a stronger than expected interaction (p=0.0007) between anxiety, sex, allelic 
variation at the rs2513280 locus and alcohol intake as measured by AUDIT score. B. 
